Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm to Participate at Upcoming Investor Conferences
NEWTON, Mass., Sept. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:
2024年9月3日，馬薩諸塞州牛頓——Karyopharm Therapeutics Inc.（納斯達克：KPTI）一家在商業化階段的藥品公司，開創了新型癌症治療方法，今天宣佈該公司的高級管理團隊將參加9月份以下投資者會議：
H.C. Wainwright 26th Annual Global Investment Conference
Format: Podium presentation
Date: Tuesday, September 10, 2024
Time: 9:00 a.m. ET
漢肯萊特第26屆全球投資大會
格式：講臺演講
日期：2024年9月10日星期二
時間：美國東部時間上午9:00
Baird 2024 Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 11, 2024
Time: 10:50 a.m. ET
貝爾德2024全球醫療保健大會
形式：座談會
日期：2024年9月11日，星期三
時間：上午10:50 ET
A live webcast of these events, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, , and will be available for replay following the event.
這些活動的現場網絡直播以及配套幻燈片可以在公司網站的"事件和演示"欄目下訪問，並且將在活動結束後提供重播。
About Karyopharm Therapeutics
關於Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics Inc.（納斯達克：KPTI）是一家商業藥品公司，其致力於開發先驅性的癌症治療方法，其動力源於對患癌症患者非凡的力量和勇氣的信仰。自創立以來，Karyopharm一直是口服複合物應對核蛋白質輸運異常的行業領導者，這是腫瘤發生的基本機制。 Karyopharm的主要化合物和首個一類口服exportin 1（XPO1）抑制劑XPOVIO（selinexor）已獲得美國批准，並由該公司在三種腫瘤適應症中銷售。 它還在越來越多的境外領域和國家獲得了各種適應症的監管批准，包括歐洲、中國和英國（作爲NEXPOVIO）。 Karyopharm的重點管道針對多種高需求腫瘤的適應症，包括多發性骨髓瘤、子宮內膜癌、骨髓纖維化和瀰漫性大B細胞淋巴瘤（DLBCL）。 獲得更多關於我們人員、科學和管道的信息，請訪問網站，並在LinkedIn和X上關注我們@Karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的註冊商標。本新聞稿中提到的任何其他商標均爲其各自所有者的財產。
SOURCE Karyopharm Therapeutics Inc.
消息來源：Karyopharm Therapeutics Inc.
譯文內容由第三人軟體翻譯。